+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 0Minutes - 96Hours
All Genders
ID06897839

Evaluating Zelpultide Alfa for Preventing Bronchopulmonary Dysplasia in High-Risk Preterm Babies Using Standard Care Compared to Placebo

Led by Airway Therapeutics, Inc. · Updated on 2026-10-09

366

Participants Needed

49

Research Sites

108 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the ability of an investigational drug called Zelpultide Alfa to reduce the occurrence of Bronchopulmonary Dysplasia BPD in extremely premature babies. This is a randomized, double-blind, placebo-controlled phase 2b3 study conducted at multiple centers. The study is designed in two parts Part 1 focuses on dose selection and exploratory evaluation of safety and effectiveness, while Part 2 confirms the findings using the selected dose from Part 1. In Part 1, participants will be randomly assigned to one of three groups receiving standard care plus either 4 mgkg or 6 mgkg of Zelpultide Alfa, or a placebo administered as air-sham. In Part 2, participants will be randomized to receive either the selected dose of Zelpultide Alfa with standard care or placebo with standard care. Treatments are given by intratracheal administration up to seven times, every 24 hours while the babies remain intubated. Participants will be closely monitored through the study period with assessments for the incidence of moderate to severe BPD or death by 36 weeks postmenstrual age. Other measures include ventilator-free days, oxygen use, extubation rates, survival, hospitalizations, and adverse events. Safety and immune responses will be tracked until hospital discharge or 36 weeks postmenstrual age, with follow-up continuing up to 24 months corrected age.

CONDITIONS

Brief Title

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

Research Team

A

Alan Wolk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here